Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.
Danahay H, Gosling M, Fox R, Lilley S, Charlton H, Hargrave JD, Schofield TB, Hay DA, Went N, McMahon P, Marlin F, Scott J, Vile J, Hewison S, Ellam S, Brown S, Sabater J, Kennet G, Lightowler S, Collingwood SP.
Danahay H, et al. Among authors: mcmahon p.
Eur J Med Chem. 2025 Jan 15;282:117040. doi: 10.1016/j.ejmech.2024.117040. Epub 2024 Nov 8.
Eur J Med Chem. 2025.
PMID: 39561495
Free article.